Cancer treatment: Boron neutron capture therapy/BNCT treatment start: Developed by Kyoto University/Sumitomo Heavy Industries
Cancer treatment:
Fukushima/Cerebral Neurological Institute (South Tohoku Group):
Treatment with boron neutron capture therapy (BNCT) is attracting attention as a “next-generation radiation cancer treatment method”.
It was the first private hospital in the world to start at Minami-Tohoku BNCT Research Center (Director Yoshihiro Takai).
BNCT device:
Jointly developed by Kyoto University and Sumitomo Heavy Industries.
From 2018 to 2019, we conducted a “clinical study for cancers in the head and neck of the neck and above.”
A total of 21 clinical trials of head and neck cancer were conducted.
Clinical trial results:
Local effect on day 90
There are 5 cases of “complete response” where the cancer disappeared,
There were 10 cases of “partial response” that decreased by 30% or more,
The “response rate”, which indicates the proportion of patients whose cancer has shrunk or disappeared, is 71.4%.
Two-year survival rate is 85%:
Most of the adverse events that occurred in patients were mild.
Director Takai explained that “effective and safe treatment“.
Fukushima/Koriyama (Sankei Shimbun)
https://news.yahoo.co.jp/articles/4f9b9719bd630faae9cc94a1d4d2aa968a12a27e
The world’s first male patient with pharyngeal cancer was treated with the accelerator-based BNCT (Boron Neutron Capture Therapy)
on May 26, 2020 at Southern TOHOKU BNCT Research Center, Southern TOHOKU Hospital Group.
At 11 a.m., the Founder and Chairman of the Board Dr. Kazuo Watanabe was invited to press the button to switch on the BNCT device.
The radiotherapy
was given by Prof. Yoshihiro Takai, Director of BNCT Research Center and Dr. Katsumi Hirose, Vice Director of BNCT Research Center.
The male patient in his 50s
was successfully treated. He is our center’s first clinical case since the AB-BNCT system and boron drug obtained an approval from Japanese government in March 2020.
BNCT treatment
will be covered by national health insurance in Japan from June 2020.
BNCT, which is one of particle beam therapies, causes reactions between low-energy thermal neutrons and tumor-seeking boron compounds to destroy cancer cells with pinpoint accuracy.
In addition, BNCT is a body-friendly treatment that can minimize negative effects to normal cells and the burdens to patients.
Locally unresectable recurrent or unresectable advanced head and neck cancer with radiation resistant is expected to become indications.
Clinical trials will aim to expand other indications in the near future. For full details visit
http://southerntohoku-bnct.com/
Southern TOHOKU Hospital Group
http://www.sthg-jp.com/motion.asp?newsid=9220&menuid=10523&lgid=1&siteid=100511